Smart Technology Empowers Healthcare: Sonosemi Completes Nearly RMB 100 Million Pre-A Financing

Shockwave Balloon Catheter: A type of intravascular lithotripsy device used within arterial vessels. Calcified arterial stenosis often leads to inadequate lesion expansion, complicating stent delivery or preventing complete stent expansion. The shockwave balloon intermittently releases acoustic pressure waves at the site of calcified vascular lesions to fracture calcified plaques. Following plaque fracture, the calcified lesions can be adequately dilated using lower balloon inflation pressures.

The intravascular lithotripsy system comprises a shockwave balloon catheter, an intracorporeal shockwave generator, and a control handle. The control handle is connected to both the shockwave balloon catheter and the intracorporeal shockwave generator. Its control buttons enable the activation or deactivation of the intracorporeal shockwave generator to initiate or terminate intravascular lithotripsy treatment, ensuring excellent safety, convenience, and reliability.

2020 marked the company's founding year. Focusing on the cardiovascular and cerebrovascular sector, and centering on technological innovation and product development for vascular implantable and interventional medical devices, the company has achieved a series of significant milestones. Additionally, it successfully completed its seed, angel, and current Pre-A rounds of equity financing, laying a solid foundation for its subsequent development.

Mr. Liu Bin, Chairman and General Manager of SONOSEMI, stated: "First of all, thank you to both new and existing investors for your recognition of SONOSEMI. 2020 was an extraordinary year, during which the company achieved leapfrog development in just twelve months—a milestone made possible by the steadfast support of our shareholders. Historically, every major advancement in semiconductor technology has profoundly impacted fields such as computing, communications, and medical technology. China's cardiovascular and cerebrovascular medical device and high-value medical consumables industry has evolved over the past two decades. We believe that smart technologies, epitomized by next-generation semiconductors, will empower the cardiovascular and cerebrovascular consumables sector, thereby ushering the industry's development into a new paradigm."

Dr. Guo Yi, Founding Managing Partner of Ruijian Capital, stated: “The vascular implant and intervention sector is evolving from an era dominated by traditional passive devices to a dual-track era where both passive and active technologies are deployed in tandem. It is foreseeable that over the next 3 to 5 years, a number of outstanding companies will emerge in China’s active implant and intervention sector. Backed by core technologies, committed to benefiting patients, guided by clinical needs, and seizing the opportunity of domestic substitution, they are poised for rapid growth in the short term. SONOSEMI stands out as a leading player among them. In the active implant and intervention field, SONOSEMI boasts a highly robust and innovative product pipeline. We are deeply pleased to participate in SONOSEMI’s capitalization journey.”

“Mr. Liu Bin, founder of SONOSEMI, is a natural-born entrepreneur. Having worked at Huawei for many years, we are confident that he will instill Huawei's outstanding corporate DNA into SONOSEMI's team, and we believe that under his leadership, the SONOSEMI team will forge ahead at full speed in this field. Ruijian Capital focuses on investing in homegrown innovative enterprises driven by cutting-edge hard tech, and remains committed to standing alongside outstanding entrepreneurs to make our own contributions to public healthcare. We look forward to partnering with SONOSEMI to envision with insight and lead the future.”

Mr. Xia Kun, Executive Partner of Jiuzhi Xinfly, stated: “Adhering to an investment philosophy focused on high-quality, innovative medical technology companies in the pan-vascular field, Jiuzhi Xinfly highly recognizes SONOSEMI's corporate strategy, product positioning, and R&D direction. As one of SONOSEMI's early investors, we believe the company holds a distinct advantage in the active vascular intervention sub-sector. We are highly confident in the team's technical foundation and sustained R&D capabilities. Furthermore, we deeply admire the pragmatic, rigorous, and efficient work style of founder Mr. Liu Bin and his team. We wish SONOSEMI new achievements as it embarks on this new starting point and reaches new heights!”

Dr. Shi Lei, Executive Director of Stone Capital, stated: “Vascular intervention has consistently been a sector that Stone Capital has long favored and strategically invested in. The leapfrog development of active vascular intervention in recent years has brought significant benefits to both physicians and patients. As a leading enterprise in active vascular intervention, we are particularly impressed by the innovation, efficiency, dedication, and professional expertise of SONOSEMI’s founder, Mr. Liu, and his team. Likewise, Stone Capital remains firmly optimistic about innovative medical device enterprises like SONOSEMI that are grounded in China’s national conditions and industrial context. We look forward to collaborating with the company and all shareholders to jointly drive its substantial and sustained development.”

SONOSEMI is a high-tech enterprise specializing in the research, development, and manufacturing of active vascular implantable and interventional medical devices. Its main products include active interventional high-value medical consumables such as shockwave balloon catheters and ultrasonic catheters, covering cardiovascular and cerebrovascular clinical fields including coronary artery disease, peripheral vascular disease, and structural heart disease. Founded in 2020 and headquartered in Shenzhen, the company’s product development team comprises professionals from renowned medical device and ICT enterprises, bringing extensive design and development expertise in medical sensors, vascular interventional devices, and console systems. We are committed to continuous technological innovation in medical sensor chip technology, driving the large-scale clinical application of novel sensor-based high-value medical consumables in the healthcare sector. By consistently creating value for both physicians and patients, we strive to be a leading enabler of smart healthcare.